JP2014504851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504851A5 JP2014504851A5 JP2013540008A JP2013540008A JP2014504851A5 JP 2014504851 A5 JP2014504851 A5 JP 2014504851A5 JP 2013540008 A JP2013540008 A JP 2013540008A JP 2013540008 A JP2013540008 A JP 2013540008A JP 2014504851 A5 JP2014504851 A5 JP 2014504851A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- polypeptide
- bacterium
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 241000894006 Bacteria Species 0.000 claims 6
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000001018 virulence Effects 0.000 claims 3
- 241000186779 Listeria monocytogenes Species 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 108700016271 Listeria monocytogenes actA Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 101100385342 Synechocystis sp. (strain PCC 6803 / Kazusa) cry gene Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 101150046348 inlB gene Proteins 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 101150036926 phrB gene Proteins 0.000 claims 1
- 101150079601 recA gene Proteins 0.000 claims 1
- 101150005573 uvrA gene Proteins 0.000 claims 1
- 101150060445 uvrB gene Proteins 0.000 claims 1
- 101150003576 uvrC gene Proteins 0.000 claims 1
- 101150073340 uvrD gene Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41485010P | 2010-11-17 | 2010-11-17 | |
| US61/414,850 | 2010-11-17 | ||
| PCT/US2011/061164 WO2012068360A1 (en) | 2010-11-17 | 2011-11-17 | Methods and compositions for inducing an immune response to egfrviii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504851A JP2014504851A (ja) | 2014-02-27 |
| JP2014504851A5 true JP2014504851A5 (enExample) | 2015-01-08 |
| JP5998370B2 JP5998370B2 (ja) | 2016-09-28 |
Family
ID=46084412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540008A Expired - Fee Related JP5998370B2 (ja) | 2010-11-17 | 2011-11-17 | Egfrviiiに対する免疫応答を誘発する方法および組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9200057B2 (enExample) |
| EP (1) | EP2640842B1 (enExample) |
| JP (1) | JP5998370B2 (enExample) |
| CN (1) | CN103415620B (enExample) |
| CA (1) | CA2818353A1 (enExample) |
| CY (1) | CY1120622T1 (enExample) |
| DK (1) | DK2640842T3 (enExample) |
| ES (1) | ES2684684T3 (enExample) |
| HR (1) | HRP20181343T1 (enExample) |
| HU (1) | HUE039747T2 (enExample) |
| LT (1) | LT2640842T (enExample) |
| PL (1) | PL2640842T3 (enExample) |
| PT (1) | PT2640842T (enExample) |
| RS (1) | RS57630B1 (enExample) |
| SI (1) | SI2640842T1 (enExample) |
| SM (1) | SMT201800444T1 (enExample) |
| WO (1) | WO2012068360A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| SI2640842T1 (sl) * | 2010-11-17 | 2018-09-28 | Aduro Biotech, Inc. | Postopki in sestavki za induciranje imunskega odziva na EGFRvIII |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| JP6257607B2 (ja) | 2012-06-08 | 2018-01-10 | アデュロ バイオテック,インコーポレイテッド | 癌免疫療法のための組成物および方法 |
| CA2888678A1 (en) | 2012-11-06 | 2014-05-15 | Aduro Biotech, Inc. | Facultatively attenuated bacterial species and methods of preparation and use thereof |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| MX361680B (es) | 2012-12-13 | 2018-12-13 | Aduro Biotech Inc | Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso. |
| SG11201502792TA (en) | 2012-12-27 | 2015-05-28 | Aduro Biotech Inc | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| JP2016518140A (ja) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | I型インターフェロンの環状ジヌクレオチド誘導法 |
| ES2754269T3 (es) | 2013-05-18 | 2020-04-16 | Aduro Biotech Inc | Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| SG11201608820WA (en) * | 2014-04-24 | 2016-11-29 | Advaxis Inc | Recombinant listeria vaccine strains and methods of producing the same |
| WO2016061115A1 (en) | 2014-10-13 | 2016-04-21 | Providence Health & Services-Oregon D/B/A Providence Portland Medical Center | Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof |
| SG11201702857PA (en) * | 2014-10-14 | 2017-05-30 | Univ Pennsylvania | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
| EP3215139B1 (en) | 2014-11-03 | 2020-08-19 | Cerus Corporation | Compositions and methods for improved car-t cell therapies |
| CA2979215A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| CN107750256A (zh) | 2015-04-13 | 2018-03-02 | 艾杜罗生物科技公司 | 表皮生长因子受体变体iii‑间皮素融合物及其使用方法 |
| JP2018512165A (ja) * | 2015-04-13 | 2018-05-17 | アデュロ バイオテック,インコーポレイテッド | 癌の治療のための免疫原性融合タンパク質 |
| US20160316247A1 (en) * | 2015-04-27 | 2016-10-27 | Ericsson Ab | Program and device class entitlements in a media platform |
| CN107847611A (zh) * | 2015-05-26 | 2018-03-27 | 阿德瓦希斯公司 | 个性化的基于递送载体的免疫疗法及其用途 |
| EP3313975A4 (en) * | 2015-06-24 | 2019-03-13 | Advaxis, Inc. | MANUFACTURING DEVICE AND METHOD FOR PERSONALIZED ADMINISTRATION OF VECTOR-BASED IMMUNOTHERAPY |
| US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| US10526609B2 (en) * | 2016-08-01 | 2020-01-07 | Aduro Biotech, Inc. | Protein expression enhancer sequences and use thereof |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| ES3029080T3 (en) | 2017-10-10 | 2025-06-23 | Seattle Project Corp | Neoantigen identification using hotspots |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| WO2021014398A1 (en) * | 2019-07-23 | 2021-01-28 | University Of Rijeka Faculty Of Medicine | Integrated human cytomegalovirus / glioblastoma vaccine |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
| US5783415A (en) | 1991-03-29 | 1998-07-21 | Genentech, Inc. | Method of producing an IL-8 receptor polypeptide |
| IT1262895B (it) | 1992-03-02 | 1996-07-22 | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
| US6379943B1 (en) | 1999-03-05 | 2002-04-30 | Merck & Co., Inc. | High-efficiency Cre/loxp based system for construction of adenovirus vectors |
| US5709999A (en) * | 1994-08-12 | 1998-01-20 | Myriad Genetics Inc. | Linked breast and ovarian cancer susceptibility gene |
| US7794729B2 (en) * | 1994-11-08 | 2010-09-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for immunotherapy of cancer |
| US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| DE69532767T2 (de) * | 1994-11-28 | 2004-08-12 | Thomas Jefferson University | Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III |
| US5888530A (en) | 1995-07-21 | 1999-03-30 | The General Hospital Corporation | Method of enhancing delivery of a pharmaceutical formulation |
| US6099848A (en) | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
| WO2002097044A2 (en) * | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| CA2486980A1 (en) | 2002-05-29 | 2003-12-11 | The Regents Of The University Of California | Attenuated listeria spp. and methods for using the same |
| WO2004006837A2 (en) | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| JP4545151B2 (ja) | 2003-02-06 | 2010-09-15 | シーラス コーポレイション | 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法 |
| WO2004084936A2 (en) | 2003-02-06 | 2004-10-07 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
| US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| CA2628282C (en) * | 2005-11-02 | 2015-04-07 | John H. Sampson | Concurrent chemotherapy and immunotherapy |
| WO2007117371A2 (en) | 2006-03-01 | 2007-10-18 | Anza Therapeutics, Inc. | Engineered listeria and methods of use thereof |
| JP5347135B2 (ja) * | 2006-03-01 | 2013-11-20 | アドゥロ バイオテック | 遺伝子工学操作されたlisteriaおよびその使用方法 |
| WO2009012488A1 (en) * | 2007-07-19 | 2009-01-22 | Duke University | Assay for human anti-egrf variant iii antibodies |
| CA2724649A1 (en) * | 2008-05-19 | 2009-11-26 | Anza Therapeutics, Inc. | Compositions comprising prfa* mutant listeria and methods of use thereof |
| KR20110045010A (ko) * | 2008-07-24 | 2011-05-03 | 아두로 바이오테크 | C형 간염의 치료를 위한 조성물 및 방법 |
| TWI580431B (zh) * | 2008-08-19 | 2017-05-01 | 腫瘤療法 科學股份有限公司 | Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗 |
| SI2640842T1 (sl) * | 2010-11-17 | 2018-09-28 | Aduro Biotech, Inc. | Postopki in sestavki za induciranje imunskega odziva na EGFRvIII |
-
2011
- 2011-11-17 SI SI201131548T patent/SI2640842T1/sl unknown
- 2011-11-17 JP JP2013540008A patent/JP5998370B2/ja not_active Expired - Fee Related
- 2011-11-17 CN CN201180062129.XA patent/CN103415620B/zh not_active Expired - Fee Related
- 2011-11-17 PT PT11841347T patent/PT2640842T/pt unknown
- 2011-11-17 ES ES11841347.5T patent/ES2684684T3/es active Active
- 2011-11-17 CA CA2818353A patent/CA2818353A1/en not_active Abandoned
- 2011-11-17 HR HRP20181343TT patent/HRP20181343T1/hr unknown
- 2011-11-17 PL PL11841347T patent/PL2640842T3/pl unknown
- 2011-11-17 SM SM20180444T patent/SMT201800444T1/it unknown
- 2011-11-17 DK DK11841347.5T patent/DK2640842T3/en active
- 2011-11-17 EP EP11841347.5A patent/EP2640842B1/en active Active
- 2011-11-17 LT LTEP11841347.5T patent/LT2640842T/lt unknown
- 2011-11-17 WO PCT/US2011/061164 patent/WO2012068360A1/en not_active Ceased
- 2011-11-17 HU HUE11841347A patent/HUE039747T2/hu unknown
- 2011-11-17 RS RS20180979A patent/RS57630B1/sr unknown
- 2011-11-17 US US13/988,076 patent/US9200057B2/en not_active Expired - Fee Related
-
2015
- 2015-11-25 US US14/952,470 patent/US9775891B2/en not_active Expired - Fee Related
-
2017
- 2017-10-02 US US15/722,908 patent/US20180021420A1/en not_active Abandoned
-
2018
- 2018-08-27 CY CY181100893T patent/CY1120622T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504851A5 (enExample) | ||
| Crocquet-Valdes et al. | Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis | |
| JP2010508861A (ja) | 抗原およびタンパク質毒素をコードする異種ヌクレオチド配列からなる担体としての微生物、その生成方法、ならびにその使用 | |
| US20090297552A1 (en) | Flagellin polypeptide vaccines | |
| CN112979829B (zh) | 融合蛋白及其在制备靶向新冠病毒sars-cov-2的疫苗中的应用 | |
| RU2677799C2 (ru) | Модифицированные суперспиральные белки с улучшенными свойствами | |
| KR20160130216A (ko) | 헤테로올리고머 미코박테리아 항원의 융합물 | |
| JP2011529077A (ja) | C型肝炎の治療のための組成物および方法 | |
| JP2009540801A5 (enExample) | ||
| JP2012515557A5 (enExample) | ||
| CN107847575A (zh) | 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物 | |
| WO2015004627A1 (en) | Mutated and bacteriophage t4 nanoparticle arrayed f1-v immunogens from yersina pestis as next generation plague vaccines | |
| JP2018501260A (ja) | 人工多抗原融合タンパク質およびその製造と使用 | |
| JP2008521431A (ja) | 破壊されたフラゲリン遺伝子を含むグラム陽性細菌細胞、フラゲリンベースの融合タンパク質及び金属イオンの液体からの除去における使用 | |
| US9925259B2 (en) | Immunogenic polypeptide surface layer-expressing bifidobacterium | |
| Kim et al. | Expression of Helicobacter pylori cag12 gene in Lactococcus lactis MG1363 and its oral administration to induce systemic anti-Cag12 immune response in mice | |
| CN107723269B (zh) | 重组鼠伤寒沙门菌二价疫苗株的构建方法及所得株和应用 | |
| WO2022034221A1 (en) | Salmonella vaccine for the treatment of coronavirus | |
| CA2730741C (en) | Self-replicating vector lacking an antibiotic-resistance gene | |
| Kim et al. | Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice | |
| EP3562504B1 (en) | Dna vaccine comprising a polynucleotide sequence encoding a fusion protein encompassing a plant protein signal sequence | |
| WO2009127766A1 (es) | Sistema para la expresión de péptidos sobre la superficie bacteriana | |
| US20240254167A1 (en) | Genetically modified clostridium strains expressing recombinant antigens and uses thereof | |
| CN106170551B (zh) | 生产不耐热肠毒素b亚单位的质粒、方法及其套组 | |
| CN104127883A (zh) | 以hsp65为表位支架的多t细胞表位结核基因疫苗 |